N Engl J Med 2022 Jun 05
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
Abstract
Background
Among breast cancers without human epidermal growth factor receptor 2 (HER2) amplification, overexpression, or both, a large proportion express low levels of HER2 that may be targetable. Currently available HER2-directed therapies have been ineffective in patients with these "HER2-low" cancers.
Methods
We conducted a phase 3 trial involving patients with HER2-low metastatic breast cancer who had received one or two previous lines of chemotherapy. (Low expression of HER2 was defined as a score of 1+ on immunohistochemical [IHC] analysis or as an IHC score of 2+ and negative results on in situ hybridization.) Patients were randomly assigned in a 2:1 ratio to receive trastuzumab deruxtecan or the physician's choice of chemotherapy. The primary end point was progression-free survival in the hormone receptor-positive cohort. The key secondary end points were progression-free survival among all patients and overall survival in the hormone receptor-positive cohort and among all patients.
Results
Of 557 patients who underwent randomization, 494 (88.7%) had hormone receptor-positive disease and 63 (11.3%) had hormone receptor-negative disease. In the hormone receptor-positive cohort, the median progression-free survival was 10.1 months in the trastuzumab deruxtecan group and 5.4 months in the physician's choice group (hazard ratio for disease progression or death, 0.51; P<0.001), and overall survival was 23.9 months and 17.5 months, respectively (hazard ratio for death, 0.64; P = 0.003). Among all patients, the median progression-free survival was 9.9 months in the trastuzumab deruxtecan group and 5.1 months in the physician's choice group (hazard ratio for disease progression or death, 0.50; P<0.001), and overall survival was 23.4 months and 16.8 months, respectively (hazard ratio for death, 0.64; P = 0.001). Adverse events of grade 3 or higher occurred in 52.6% of the patients who received trastuzumab deruxtecan and 67.4% of those who received the physician's choice of chemotherapy. Adjudicated, drug-related interstitial lung disease or pneumonitis occurred in 12.1% of the patients who received trastuzumab deruxtecan; 0.8% had grade 5 events.
Conclusions
In this trial involving patients with HER2-low metastatic breast cancer, trastuzumab deruxtecan resulted in significantly longer progression-free and overall survival than the physician's choice of chemotherapy. (Funded by Daiichi Sankyo and AstraZeneca; DESTINY-Breast04 ClinicalTrials.gov number, NCT03734029.).
Related Questions
What imaging surveillance for ILD do you utilize for patients with HER2+ breast cancer receiving adjuvant T-DXd?
I utilize high-resolution CT (HRCT) of the chest to monitor patients receiving adjuvant T-Dxd. Per DESTINY-Breast05, a protocol mandate, ILD surveillance with low-dose non-contrast (LDCT) was done at baseline and 6 weeks, followed by every 12 weeks during treatment and 6 weeks post-therapy completio...
How will you sequence Dato-DXd among available therapies for HR positive, HER2-0 metastatic breast cancer?
While the approval of Dato-DXd for advanced HR+ HER2- breast cancer offers another TROP2 ADC with an improvement in clinical outcomes, there remain several unanswered questions and uncertainty about how to best utilize and sequence the ADCs for metastatic breast cancer. For patients with HR+ HER2 lo...
How do you sequence everolimus/endocrine therapy versus fam-trastuzumab deruxtecan after progression on CDK4/6i in metastatic ER+ HER2 low breast cancer?
Since the DESTINY-Breast04 trial required patients to be endocrine therapy resistant and have received 1-2 prior lines of systemic chemotherapy for metastatic disease, I would consider Enhertu only after patients progressed on everolimus and endocrine therapy.
Would you still offer trastuzumab deruxtecan in a patient with progressive HR+/HER2+ breast cancer who has prior history of cell cycle inhibitor related pneumonitis?
In DESTINY-Breast04, about 70% of patients were CDK4/6i treated but were excluded if they had a history of ILD/pneumonitis. So, we don't know if this patient is at higher risk of pneumonitis with trastuzumab deruxtecan. I would consider it if her previous pneumonitis was mild and fully resolved with...
Since the publication of DESTINY-Breast-04 have you implemented new institutional practices for characterization of HER2-low disease given known limitations in pathologist IHC evaluation?
Since the publication of DESTINY-Breast04, new institutional practices for the characterization of HER2-low disease have been implemented in my practice. The Ventana antibody is utilized, with the approved companion diagnostic recommended. However, it should be noted that the study found the Ventana...
What factors do you use to decide between trastuzumab-deruxtecan and sacituzumab govitecan in HER2-low metastatic breast cancer?
Updated answer - 11/26/2024There is currently limited data to guide the efficacy of trastuzumab deruxtecan (T-DXd) after progression on sacituzumab or vice versa. Since both drugs have a topoisomerase 1 inhibitor payload, cancers resistant to topoisomerase 1 inhibitors may be resistant to both drugs...
For patients with metastatic HER2-null breast cancer, do you offer trastuzumab deruxtecan based on the DAISY trial results?
DAISY trial was a small trial and the outcome was hypothesis-generating rather than practice-changing. With that said, I offer trastuzumab deruxtecan to patients with metastatic breast cancer even if HER2 IHC on biopsy of metastatic disease was 0 but historically, their primary tumor tested at least...
What criteria would you use to decide between trastuzumab-deruxtecan and sacituzumab govitecan in HER2 low metastatic TNBC given T-DXd approval in HER2 low breast cancer?
There are currently unfortunately no biomarkers to select participants for antibody drug conjugate therapies, including sacituzumab and trastuzumab deruxtecan for HER2 low metastatic TNBC. The studies evaluating sacituzumab govitecan and trastuzumab deruxtecan had different I/E criteria, including w...
Are there differences in T-DXd efficacy along the spectrum of HER2 IHC expression to impact treatment decisions or sequencing?
There do not appear to be differences in T-DXd efficacy along the spectrum of HER2 expression in these low HER2-expressing tumors as seen in Figure S2 and Figure S4. Reviewing the waterfall plot (Fig Supp 4), we see complete responses in approximately as many patients with IHC 1+ as those with IHC 2...
In patients with metastatic hormone receptor-positive, HER2-low breast cancer, how many and which lines of therapy would you recommend prior to using trastuzumab deruxtecan?
In spite of the exciting results observed with trastuzumab deruxtecan in DESTINY-Breast04, endocrine based therapy continues to be the most appropriate first line choice for the majority of patients with hormone receptor-positive, HER2-negative disease, particularly as we are now seeing median overa...
If there is HER2-low discordance between primary and subsequent breast cancer biopsies, in which scenarios would you choose to use trastuzumab deruxtecan?
Because of the potential heterogeneity of HER2 expression, I would still offer T-DXd for these patients. In addition, HER2 IHC 0 may not exclude T-DXd activity based on the DAISY trial.
What is trastuzumab deruxtecan's activity for patients with CNS+ disease?
The DESTINY-Breast04 trial excluded patients with active CNS metastases so the study does not provide information on the activity of this drug in HER2-low CNS disease. In HER2-positive disease, however, CNS activity has been observed with trastuzumab deruxtecan; among patients evaluated for CNS resp...
When defining HER2-low status in breast cancer, are there certain IHC assays/techniques that are preferred?
As with most IHC evaluations, there are significant variations between grading pathologists. During ASCO 2022, the discussant for DB4, Dr. Patricia LoRusso very eloquently discussed this issue with IHC and specifically, how a more reproducible, quantifiable assay is needed. Until that time, IHC rema...
How will you approach treatment sequencing and use of trastuzumab deruxtecan in hormone receptor-negative, HER2-low breast cancer?
Results from the DESTINY-Breast04 (DB4) trial [1] has created a new therapeutic option for patients with triple negative breast cancer (TNBC) that is low HER2 expressing (IHC 1+ or 2+ but FISH negative). In the DB4 trial, only 11% of participants had hormone receptor negative, HER2 low breast cancer...
Do you recommend maintenance immunotherapy after CR on chemotherapy for patients with metastatic TNBC?
The phase 2, KEYNOTE-158 study done in patients with metastatic solid tumors who progressed on at least 1 line of treatment, showed that 29% of 102 patients with TMB high status had an objective response compared to only 6% of 688 patients who had TMB low status, leading to FDA approval for tumor ag...
What are your top takeaways in Breast Cancer from ASCO 2022?
DESTINY-Breast04: it is phase III study of Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice in HER2-low metastatic breast cancer (MBC). This study showed improved progression-free survival (PFS) and overall survival (OS) with T-DXd vs standard therapy in this patient population. T-...
Would you recommend olaparib for a patient with germline BRCA1 mutation and HER2+ metastatic breast cancer who has progressed through multiple lines of HER2-directed therapy including trastuzumab deruxtecan?
Although OlympiAD (Robson et al., PMID 28578601) and EMBRACA (Litton et al., PMID 30110579) studied olaparib and talazoparib in HER2negative gBRCA mutant metastatic breast cancer, the activity is based on the mechanism of synthetic lethality in BRCA deficient tumors. Thus, it is reasonable to think ...
Are there strategies to mitigate the risk of developing ILD/pneumonitis while using trastuzumab deruxtecan?
The most important strategy is global awareness of ILD as a potentially serious complication that may initially present with subtle signs. Patients and all care team members must not only be aware but remind others in the patient/family care circle. This needs to be reinforced regularly. The recogni...
Would a HER2 mutation on NGS of a biopsy of a breast cancer liver metastasis change your management if the met is HER2- by IHC with the initial localized disease being HER2+?
Activating ERBB2 (HER2) mutations can be seen in breast cancer without amplification of the gene in 1-3% of cases, but can be higher in patients who have been treated with hormonal therapy for hormone receptor-positive disease at a higher rate, perhaps 5% or even as high as 10% being reported in lob...
What is the preferred sequence of systemic therapy in a patient with endocrine resistant HR+ metastatic breast cancer?
Several factors can affect the next line of therapy in my view like disease free interval (DFI) before the patient developed metastatic disease, duration of response (if any) to prior endocrine with/without CDK4/6i, disease burden, patient's performance status and competing comorbidity. If the patie...